MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 3, 2005; DOI: 10.1124/mol.105.015404


0026-895X/06/6902-440-451$20.00
Mol Pharmacol 69:440-451, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.105.015404v1
69/2/440    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, G.-S.
Right arrow Articles by Tai, M.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, G.-S.
Right arrow Articles by Tai, M.-H.

Gene Transfer of Pro-opiomelanocortin Prohormone Suppressed the Growth and Metastasis of Melanoma: Involvement of {alpha}-Melanocyte-Stimulating Hormone-Mediated Inhibition of the Nuclear Factor {kappa}B/Cyclooxygenase-2 PathwayFormula

Guei-Sheung Liu, Li-Fen Liu, Che-Jen Lin, Jui-Cheng Tseng, Ming-Ju Chuang, Hing-Chung Lam, Jenn-Kuen Lee, Lin-Cheng Yang, Julie Hwa Yu Chan, Shen-Long Howng, and Ming-Hong Tai

Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan (G.-S.L., S.-L.H., M.-H.T.); Department of Medical Education & Research (G.-S.L., C.-J.L., H.-C.L., J.H.Y.C., M.-H.T.), Division of Allergy, Immunology, and Rheumatology (J.-C.T.), and Division of Endocrinology and Metabolism, Department of Medicine (M.-J.C., H.-C.L., J.-K.L.), Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Biological Science and Technology (L.-F.L.) and Department of Anesthesiology, E-DA Hospital, I-Shou University (L.-C.Y.), Kaohsiung, Taiwan; and Department of Biological Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan (M.-H.T.)

Pro-opiomelanocortin (POMC) is a prohormone of various neuropeptides, including corticotropin, {alpha}-melanocyte-stimulating hormone ({alpha}-MSH), and beta-endorphin (beta-EP). POMC neuropeptides are potent inflammation inhibitors and immunosuppressants and may exert opposite influences during tumorigenesis. However, the role of POMC expression in carcinogenesis remains elusive. We evaluated the antineoplastic potential of POMC gene delivery in a syngenic B16-F10 melanoma model. Adenovirus-mediated POMC gene delivery in B16-F10 cells increased the release of POMC neuropeptides in cultured media, which differentially regulated the secretion of pro- and anti-inflammatory cytokines in lymphocytes. POMC gene transfer significantly reduced the anchorage-independent growth of melanoma cells. Moreover, pre- or post-treatment with POMC gene delivery effectively retarded the melanoma growth in mice. Intravenous injection of POMC-transduced B16-F10 cells resulted in reduced foci formation in lung by 60 to 70% of control. The reduced metastasis of POMC-transduced B16-F10 cells could be attributed to their attenuated migratory and adhesive capabilities. POMC gene delivery reduced the cyclooxygenase-2 (COX-2) expression and prostaglandin (PG) E2 synthesis in melanoma cells and tumor tissues. In addition, application of NS-398, a selective COX-2 inhibitor, mimicked the antineoplastic functions of POMC gene transfer in melanoma. The POMC-mediated COX-2 down-regulation was correlated with its inhibition of nuclear factor {kappa}B (NF{kappa}B) activities. Exogenous supply of {alpha}-MSH inhibited NF{kappa}B activities, whereas application of the {alpha}-MSH antagonist growth hormone-releasing peptide-6 (GHRP-6) abolished the POMC-induced inhibition of NF{kappa}B activities and melanoma growth in mice. In summary, POMC gene delivery suppresses melanoma via {alpha}-MSH-induced inhibition of NF{kappa}B/COX-2 pathway, thereby constituting a novel therapy for melanoma.


Received June 14, 2005; accepted November 2, 2005

Address correspondence to: Dr. Ming-Hong Tai, Department of Medical Education and Research, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung 813, Taiwan. E-mail: mhtai{at}isca.vghks.gov.tw




This article has been cited by other articles:


Home page
EndocrinologyHome page
C. Caruso, D. Durand, H. B. Schioth, R. Rey, A. Seilicovich, and M. Lasaga
Activation of Melanocortin 4 Receptors Reduces the Inflammatory Response and Prevents Apoptosis Induced by Lipopolysaccharide and Interferon-{gamma} in Astrocytes
Endocrinology, October 1, 2007; 148(10): 4918 - 4926.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
H.-C. Lam, S.-M. Kuo, M.-J. Chuang, H.-M. Keng, P.-R. Lin, G.-S. Liu, C.-M. Hsu, S.-L. Howng, and M.-H. Tai
Blockade of endothelin-1 release contributes to the anti-angiogenic effect by pro-opiomelanocortin overexpression in endothelial cells.
Experimental Biology and Medicine, June 1, 2006; 231(6): 782 - 788.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics